Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

December 31, 2028

Conditions
Metastatic Breast Cancer
Interventions
DRUG

TQB2102 Injection

TQB2102 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody-drug conjugate.

DRUG

Trastuzumab Emtansine for Injection

Trastuzumab Emtansine for Injection is HER2-targeting antibody-drug conjugate (ADC).

Trial Locations (31)

100034

NOT_YET_RECRUITING

Peking University First Hospital, Beijing

101300

NOT_YET_RECRUITING

Beijing Shunyi Hospital, Beijing

110041

NOT_YET_RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

116000

NOT_YET_RECRUITING

The Second Hospital Of Dalian Medical University, Dalian

130000

NOT_YET_RECRUITING

Jilin Cancer Hospital, Changchun

130021

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

150000

NOT_YET_RECRUITING

Affiliated Cancer Hospital Of Harbin Medical University, Harbin

154007

NOT_YET_RECRUITING

Jiamusi Tuberculosis Hospital (Jiamusi Tumor Hospital), Jiamusi

201321

NOT_YET_RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

230000

RECRUITING

Anhui Provincial Cancer Hospital, Hefei

NOT_YET_RECRUITING

The First Affiliated Hospital of Anhui Medical University, Hefei

233099

NOT_YET_RECRUITING

The First Affiliated Hospital of Anhui Medical University, Bengbu

272029

NOT_YET_RECRUITING

Affiliated Hospital Of Jining Medical University, Jining

276000

NOT_YET_RECRUITING

Linyi Cancer Hospital, Linyi

300060

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

310002

NOT_YET_RECRUITING

Hangzhou Cancer Hospital, Hangzhou

330029

NOT_YET_RECRUITING

Jiangxi Cancer Hospital, Nanchang

350000

NOT_YET_RECRUITING

Fujian Cancer Hospital, Fuzhou

410013

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

450000

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

455001

NOT_YET_RECRUITING

Anyang Cancer Hospital, Anyang

471000

NOT_YET_RECRUITING

The First Affiliated Hospital Of Henan University Of Science & Technology, Luoyang

529000

NOT_YET_RECRUITING

Jiangmen Central Hospital, Jiangmen

530028

NOT_YET_RECRUITING

Affiliated Cancer Hospital Of Guangxi Medical University, Nanning

550001

NOT_YET_RECRUITING

Cancer Hospital Of Guizhou Medical University, Guiyang

570311

NOT_YET_RECRUITING

Hainan General Hospital, Haikou

635000

NOT_YET_RECRUITING

Dazhopu Central Hospital, Dazhou

637000

NOT_YET_RECRUITING

Affiliated Hospital of North Sichuan Medical College, Nanchong

730000

NOT_YET_RECRUITING

The First Hospital Of Lanzhou University, Lanzhou

050035

NOT_YET_RECRUITING

The Fourth Hospital Of Hebei Medical University, Shijiazhuang

024000

NOT_YET_RECRUITING

Chifeng Municipal Hospital, Chifeng

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY

NCT07008976 - Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer | Biotech Hunter | Biotech Hunter